Research and Markets (http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv) has announced the addition of Decision Resources, Inc's new report "DRG Insights: CV Overview (G7)" to their offering.
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. With sales growth of 1.6% year-on-year (YoY), 2011 was a modest period for the Cardiovasculars sector.
This result reflects the fact that the two largest cardiovascular drug classes (the AIIRAs and Statins), with 2011 annual sales of $23.8b and $21.8b, respectively, have reached maturity. Throughout the forecast period, both of these key drug classes will endure sustained losses as a result of aggressive generic erosion that will set in from 2011 onwards (concomitant with the loss of patent protection for Pfizer's Lipitor and Novartis' Diovan).
Key Topics Covered:
Epidemiology & Unmet Needs
Current/Projected Market Share
Drug Sales & Forecasts for each of the following CVD Indications: Acute Coronary Syndrome (UA/NSTEMI/NSTE-ACS)
Arrhythmias (AF Ventricular)
Heart Failure (acute/chronic)
Lipid Disorders (hyperlipidemia/dyslipidemia)
Peripheral Arterial Disease
Pulmonary Arterial Hypertension
For more information visit http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv
Source: Decision Resources, IncBusiness Wire
Last updated on: 08/10/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.